These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8429536)

  • 41. Amino acid sequence determinants of extended spectrum cephalosporin hydrolysis by the class C P99 beta-lactamase.
    Zhang Z; Yu Y; Musser JM; Palzkill T
    J Biol Chem; 2001 Dec; 276(49):46568-74. PubMed ID: 11591698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydrolysis of Cefotaxime by a beta-lactamase from Bacteroides fragilis.
    Pechère JC; Guay R; Dubois J; Letarte R
    Antimicrob Agents Chemother; 1980 Jun; 17(6):1001-3. PubMed ID: 6250465
    [TBL] [Abstract][Full Text] [Related]  

  • 43. beta-Lactamase stability of cefotaxime.
    Richmond MH
    J Antimicrob Chemother; 1980 Sep; 6 Suppl A():13-7. PubMed ID: 6252144
    [No Abstract]   [Full Text] [Related]  

  • 44. Rapid and automated measurement of Km and specific Vmax values of beta-lactamases in bacterial extracts.
    Nichols WW; Hewinson RG
    J Antimicrob Chemother; 1987 Mar; 19(3):285-95. PubMed ID: 3106302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of a beta-lactamase activity in Mycoplasma capricolum transfected with the liposome-encapsulated E.coli pBR 322 plasmid.
    Nicolau C; Rottem S
    Biochem Biophys Res Commun; 1982 Oct; 108(3):982-6. PubMed ID: 6758777
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacokinetics of FK482, a new orally active cephalosporin, in animals.
    Sakamoto H; Hirose T; Nakamoto S; Hatano K; Shibayama F; Kikuchi H; Mine Y; Kuwahara S
    J Antibiot (Tokyo); 1988 Dec; 41(12):1896-905. PubMed ID: 3209481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Class C beta-lactamases operate at the diffusion limit for turnover of their preferred cephalosporin substrates.
    Bulychev A; Mobashery S
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1743-6. PubMed ID: 10390233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discrimination of extended-spectrum beta-lactamases by a novel nitrocefin competition assay.
    Papanicolaou GA; Medeiros AA
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2184-92. PubMed ID: 2073109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potentiality of yeast Candida sp. SMN04 for degradation of cefdinir, a cephalosporin antibiotic: kinetics, enzyme analysis and biodegradation pathway.
    Selvi A; Das D; Das N
    Environ Technol; 2015; 36(24):3112-24. PubMed ID: 26000889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactions of Escherichia coli TEM beta-lactamase with cephalothin and with C10-dipeptidyl cephalosporin esters.
    Mobashery S; Johnston M
    J Biol Chem; 1986 Jun; 261(17):7879-87. PubMed ID: 3519615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distribution of R plasmids conferring a permeability barrier to cephalosporins on bacteria isolated from clinical specimens.
    Ikeuchi T; Osada Y
    Microbiol Immunol; 1981; 25(7):727-35. PubMed ID: 6974301
    [No Abstract]   [Full Text] [Related]  

  • 52. Are TEM beta-lactamases encoded by pBR322 and Bluescript plasmids enzymatically indistinguishable?
    Chaibi EB; Peduzzi J; Barthelemy M; Labia R
    J Antimicrob Chemother; 1997 May; 39(5):668-9. PubMed ID: 9184372
    [No Abstract]   [Full Text] [Related]  

  • 53. Red stools and omnicef.
    Nelson JS
    J Pediatr; 2000 Jun; 136(6):853-4. PubMed ID: 10839896
    [No Abstract]   [Full Text] [Related]  

  • 54. Cefdinir associated bloody stool in Riyadh infant: A case report.
    Bahkali HA; Alshuraim RA; Alghalbi M; Mohzari YA; Asdaq SMB
    J Family Med Prim Care; 2020 Jun; 9(6):3162-3164. PubMed ID: 32984193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erratum: Cefdinir and
    Frontiers Production Office
    Front Pharmacol; 2022; 13():849039. PubMed ID: 35153803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of extended-spectrum plasmid-mediated beta-lactamases by disk diffusion.
    Sirot J
    Clin Microbiol Infect; 1996 Feb; 2 Suppl 1():S35-S39. PubMed ID: 11866860
    [No Abstract]   [Full Text] [Related]  

  • 57. Cefuroxime Resistance to Staphylococcal β-Lactamases.
    Laverdiere M; Wheeler N; Sabath LD
    Proc R Soc Med; 1977; 70(Suppl 9):72-3. PubMed ID: 20919421
    [No Abstract]   [Full Text] [Related]  

  • 58. β-Lactams and β-Lactamase Inhibitors: An Overview.
    Bush K; Bradford PA
    Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.